Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jill Avery

Nurse Practitioner, Acute Care Little Rock, AR Nurse Practitioner

NPI 1538259015 CMS profile 10880262

4301 W Markham St # 783, Little Rock, AR 72205

Open in the dashboard

General payments

$116,889

150 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jill Avery of Little Rock, AR is reported in the CMS Open Payments database as having received $116,889 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $17,503 20
2024 General $43,727 53
2023 General $55,659 77

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jill Avery
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Jill Avery were reported at $17,503. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Jill Avery Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $123 $38–$327 $132
2022 $0 $130 $44–$369 $149
2023 $55,659 $144 $49–$410 $160
2024 $43,727 $146 $48–$433 $164
2025 $17,503 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Jazz Pharmaceuticals Inc. $101,831 122 payments
  2. Pharmacyclics LLC, An AbbVie Company $7,587 8 payments
  3. E.R. Squibb & Sons, L.L.C. $6,215 12 payments
  4. Celgene Corporation $600 2 payments
  5. Janssen Biotech, Inc. $423 4 payments
  6. Regeneron Healthcare Solutions, Inc. $125 1 payment
  7. GlaxoSmithKline, LLC. $108 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $81,854 33 payments
  2. Travel and Lodging $31,458 85 payments
  3. Food and Beverage $2,977 30 payments
  4. Consulting Fee $600 2 payments
Products named General payments · program years 2023–2025
  1. ZEPZELCA $101,831 122 payments
  2. IMBRUVICA Oncology $7,587 8 payments
  3. REBLOZYL $5,660 12 payments
  4. ONUREG $855 1 payment
  5. IMBRUVICA Oncology $423 4 payments
  6. LIBTAYO $125 1 payment
  7. OJJAARA $108 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record